Form 4: iTeos Therapeutics Former 10% Owner, MPM BioImpact, Sells 1,031,931 Shares

Ansbert Gadicke, a managing partner at MPM BioImpact LLC, reports the sale of 1,031,931 shares of iTeos Therapeutics, Inc. at an average price of $8.06.

Summary

• On May 13, 2025, Ansbert Gadicke, a managing partner at MPM BioImpact LLC, reported the sale of 1,031,931 shares of iTeos Therapeutics, Inc. (ITOS) common stock.
• The shares were sold at a weighted average price of $8.06, with individual transactions ranging from $7.73 to $8.34.
• The sales were executed by various MPM BioVentures funds and UBS Oncology Impact Fund L.P.
• Following the reported transaction, the reporting persons still beneficially own 3,452,797 shares indirectly.
• Gadicke disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the large sale of shares by a significant shareholder, which could indicate a lack of confidence or simply a portfolio rebalancing. However, the remaining ownership is still substantial.

Negatives

• A significant number of shares (1,031,931) were sold by a former 10% owner, which could be perceived negatively by the market.

Risks

• Continued selling pressure from major shareholders could negatively impact the stock price.
• The market may interpret the sale as a lack of confidence in the company's future prospects.

Industry Context

Sales by significant shareholders are common in the biopharmaceutical industry, especially after periods of stock appreciation. The impact on the stock price depends on the market's interpretation of the reasons behind the sale and the overall investor sentiment towards the company.

Comparison to Industry Standards

• It is common for venture capital and private equity firms to distribute shares of publicly listed companies to their limited partners or to sell shares to realize gains on their investments.
• The size of this sale (1,031,931 shares) is relatively significant, but not uncommon for a company of iTeos Therapeutics' size and stage.
• Comparable companies like Arcus Biosciences or Gritstone Bio often see similar transactions from their major shareholders.

Stakeholder Impact

• Shareholders may react negatively to the news of a large share sale.
• The sale could create short-term selling pressure on the stock.

Key Dates

Keywords

iTeos Therapeutics, ITOS, Ansbert Gadicke, MPM BioImpact, share sale, Form 4, beneficial ownership, UBS Oncology Impact Fund